Clinical Trial

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-11
notable Enrollment reduced: 18 -> 16 participants 2026-08-11
Trial Details
NCT Number NCT07169331
Lead Sponsor BeiGene
Conditions Waldenström's Macroglobulinemia
Enrollment 16 participants
Start Date 2025-10-17
Primary Completion 2028-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10